Adjuvant (ART) and salvage radiotherapy (SRT) are two common concepts to enhance biochemical relapse free survival (BCRFS) in patients with prostate cancer (PC). We analyzed differences in outcome between ART and SRT in patients with steep decline of PSA-levels after surgery to compare outcome.
Prostate cancer incidence and mortality rates are highest among African-American men. Comorbidity burden and quality of life (QOL) challenges are also high. Many factors drive these differences; health behaviors are important modifiable contributors.
Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone.
To evaluate the safety and efficacy of focal laser ablation (FLA) in low-intermediate risk prostate cancer.
Inclusion criteria were men aged 50-75 years, prostate-specific antigen (PSA) ≤15 ng/mL, clinical stage T1c-T2a, one or two lesions (PI-RADS ≥3) on magnetic resonance imaging (MRI), and Gleason score 6 (>3 mm) or Gleason 7 on targeted biopsy.
The last five years has witnessed a remarkable evolution in the management of metastatic hormone-sensitive prostate cancer (mHSPC), with multiple agents demonstrating profound benefit in combination with initial androgen deprivation therapy (ADT).
The success of multiparametric magnetic resonance imaging (mpMRI) for reliably detecting and localizing clinically significant (cs) prostate cancer (PCa) is highly dependent on image quality. However, due to the variability of available MRI equipment including software levels and prostate MRI technologists’ (MRI radiographers’) experience, it can be challenging to consistently achieve good-quality images for detection, localization, staging, and follow-up of PCa. The first step to improve quality and reduce variability is to implement optimized acquisition protocols.
To evaluate focal high dose rate (HDR) brachytherapy in locally recurrent prostate cancer.
Patients with biochemical relapse after non-surgical primary treatment for localised prostate cancer were selected after a negative screen for metastatic disease.
To assess the impact of excluding Gleason Grade Group 1 (GG1) prostate cancer (PCa) cores from current pre-radical prostatectomy (RP) nomograms.
Multi-institutional retrospective chart review performed on all RP patients with prostate biopsy between 2008-2018.
Several small studies have reviewed the efficacy of abiraterone acetate plus prednisolone (AAP) in clinical practice outside a trial setting. We report the largest cohort study of clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients treated with AAP in a multicenter multiracial clinical setting.
To determine the prevalence and predictive value of a series of commonly used MRI criteria for posterolateral extraprostatic extension (EPE) of prostate cancer (PCa).
The presence of EPE in index lesions visible on prebiopsy mpMRI (T2w, DWI and DCE on a 3 Tesla-system) of biopsy-proven PCa patients was blindly assessed retrospectively by two radiologists with 8- and 17-years of experience on the basis of 8 commonly used staging criteria.